Taken together, our main results indicate that patients with primary tumors showing low tumor cell proliferation in combination with high PSA expression (“Ki67 low, PSA high”) will develop metastases primarily of the MetA subtype that will show a favorable response to standard ADT. The gene discussed is MKI67; the disease is neoplasm.